Archive | October, 2019

Taiwan, Leading The Way in the Asia Life Science Ecosystem – Spotlight: RESI Taiwan

17 Oct

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Historically, Taiwan has been a technology powerhouse with a ubiquitous presence in microelectronics that reach into the personal devices, homes, offices, and cars of consumers around the world.  Taiwan has established its presence in the life science industry and is a premier player in Asia, and is now making a mark on the global stage.

Taiwan is reaping the benefit of having a clear life science vision and then mastering the execution of that vision by building a world class life science innovation ecosystem.  Taiwan’s stand-out performance in life sciences begins with a well-protected IP and legal environment. Taiwan has also developed comprehensive biomedical clusters and supply chains that lead the way for the Pacific Rim players.  For drug developers, few countries can compete with their healthcare and clinical trial infrastructure. Not to mention, in 1996 they digitized the country’s 23M patient records.  When you add in their world-class NHIA database and the Taiwan Biobank, it all adds up to a superior environment for healthcare development and clinical trials.  To top it off, the government of Taiwan leads the way with holistic support and regulation, making Taiwan the go-to country for life science development.

Over the last two years, I have spent some time delving into the life science landscape of Taiwan. I always talk about the tsunami of technology surfacing around the planet. I have witnessed firsthand how Taiwan is placing itself at the forefront in the life science arena, with cross-border partnerships in the academic and private sectors producing  great results.  Taiwan has a rich entrepreneur base that is creating dynamic technology silos within drugs, devices, diagnostics and digital health. Taiwanese startups and the Taiwanese governmental programs have made Taiwan one of the top healthcare technology hubs on the planet. I have met with Taiwanese entrepreneurs who are developing next generation micro-machine technologies that will impact the way we treat and diagnose patients in a wide range of diseases. I have seen these developers using custom silicon-based medical devices that will monitor patients both inside and outside the body, feeding a new generation of data to a bevy of new AI applications.

There is so much more going on in Taiwan you really need to go there and see for yourself. Best-in-class therapeutics, robotics, medical devices and digital health…it’s all there sitting in Taiwan as we speak. LSN is helping these entrepreneurs get from a regional mindset to a global strategy for partnering and commercialization of all this technology.

Life Science Nation has partnered with Ministry of Science and Technology (MOST) and NARLabs to organize an inaugural RESI Conference in Taipei, Taiwan on November 14th.   Attending RESI Taipei will be a great chance for LSN’s global partners to get plugged into the Taiwan’s rising life science ecosystem and meet emerging startups, both local and drawn from RESI’s global network.

Global Family Office BioForum Joins RESI Asia – Part 2 of the Interview with Chuck Stetson

17 Oct

By Nono Hu, Director of Marketing, LSN

Last week, LSN released the first part of a two-part interview with Chuck Stetson, CEO, Stetson Family Office and Founder of the Global Family Office BioForum (GFOB). Part two interview continues the discussion of family office investment in early stage life science companies. Chuck will be representing GFOB at RESI Shanghai on Nov. 12th and RESI Taipei on Nov. 14th, hosting a Fireside Chat at both events to discuss the strategies GFOB employs to help promote early stage investing by partnering family offices with regional angel groups and incubator programs.

To register for RESI and check out the amazing content click here!

 

McDermott, Will & Emery Presents Expert Cross-Border Legal Content at RESI Asia

17 Oct

By Lucy Parkinson, VP of Investor Research, LSN

Cross-border investment is a growing theme in early stage life science, with investors forming global syndicates and moving new technologies toward market in multiple regions simultaneously to maximize their returns.  However, this creates significant complexities at the legal level, both from an investment perspective and also a regulatory one, not to mention creating concerns about IP protection.  Entrepreneurs are often in need of expert advice on these complexities that arise from acting globally.

RESI Shanghai Agenda

In conjunction with RESI Shanghai, our sponsors McDermott, Will & Emery are holding the 3rd China Life Science And Health Care Outbound Legal Symposium at the Ritz Carlton Pudong on November 12th.  This full day track of content from legal experts, focused on cross-border activities and investment topics, will be open to all RESI Shanghai attendees.  Additionally, McDermott, Will & Emery will present a half-day of expert legal content at RESI Taipei on November 14th.

Hot Investor Mandate: Life Science VC Firm with USA and China Offices Invests in Novel Therapeutics, Including Small Molecules, Biologics, etc.

17 Oct

A life science venture capital firm with strong China expertise and global capabilities was founded in 2017. The firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs.

The firm currently has two funds: The first $115 million fund has been fully invested. The firm is raising another $115 million fund, which more than half are closed. The firm operates offices in USA and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Technology Company Seeks Partnerships and Licensing Opportunities in Promising Medical Device Startups

17 Oct

A global technology company is dedicated to crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products.

The company’s medical business works with health care professionals to combine their innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients.

Throughout the company’s long history, the company has focused on being true to society and making people’s lives healthier, safer and more fulfilling. The company’s commitment to our purpose along with our major presence in hospitals around the world aligns with our goal to invest in future developments that will improve the experiences of providers and patients and transform Healthcare around the world.

The company is seeking partnerships and licensing relationships with early stage medical device startups worldwide. The company’s key areas of interest are endoscopes, laparoscopic devices, devices for minimally invasive surgery, and AI technologies across a wide range of specialties including ENT, gastrointestinal, respiratory, gynecology, and urology.

The company is interested in working with and supporting medical device companies with differentiated technology addressing unmet medical needs. An ideal partner would have an experienced management team with a proven track record of successful business development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm with Headquarters in Southeast Asia Makes Seed to Series B Investments Across Various Life Science Technologies, Including AI, Consumer Health, etc.

17 Oct

Founded in 2011, a venture capital firm based in Southeast Asia makes Seed to Series B investments across several key sectors including healthcare, fintech, consumer, AI, and life science services. The firm manages $200 million, and is investing from its second fund. While the firm focuses on their home country, the firm is looking for opportunities worldwide and has recently made an investment in the USA.

The firm will consider a wide variety of life science opportunities. The firm’s past investments have included pharma supply chain, AI, and healthcare services.

The firm seeks a strong and experienced management team, with a focus on entrepreneurs from elite educational institutions.  The firm focuses on India and has a strong connection with major academic institutions in their country of origin, but looks worldwide for novel technology breakthroughs to invest in.  The firm has also launched a Unified Innovation and Entrepreneurship Platform to incubate new startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Firm with USA and China Offices Invests in Highly Disruptive Technologies Within All Life Science Sectors

17 Oct

A venture capital firm founded in 2015 and based in the USA also has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 30 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →